Moderna Inc (MRNA)

NASDAQ
Currency in USD
27.35
-0.40(-1.44%)
Closed·
Pre Market
26.68-0.67(-2.45%)
·
MRNA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MRNA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.8127.93
52 wk Range
23.15145.74
Key Statistics
Edit
Prev. Close
27.35
Open
27.29
Day's Range
26.81-27.93
52 wk Range
23.15-145.74
Volume
8.33M
Average Volume (3m)
10.67M
1-Year Change
-81.49%
Book Value / Share
26.04
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRNA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
47.64
Upside
+74.17%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings upwards for the upcoming period

Moderna Inc News & Analysis

Show more

Moderna Inc Company Profile

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna Inc SWOT Analysis


mRNA Trailblaze
Moderna, a pioneer in mRNA technology, faces challenges as COVID-19 vaccine demand wanes. Explore its strategic pivot and diverse pipeline.
Financial Crossroads
With revenue declining 52.75% in the last year, Moderna aims for cash break-even by 2028. Analyst price targets range from $45 to $155.
Cancer Vaccine Promise
Delve into Moderna's cancer vaccine program, a potential $20 billion market opportunity, and its collaboration with Merck for melanoma treatment.
Pipeline Diversity
Learn about Moderna's expansive portfolio beyond COVID-19, including respiratory vaccines, rare disease treatments, and latent virus prevention.
Read full SWOT analysis

Moderna Inc Earnings Call Summary for Q1/2025

  • Moderna's Q1 2025 EPS of -$2.52 beat expectations, but revenue of $108M missed forecasts; stock fell 5.1% pre-market
  • Revenue declined 35% YoY; company reduced costs by 19%, enhancing financial stability; ended Q1 with $8.4B in cash
  • 2025 revenue guidance set at $1.5-$2.5B; targeting cost reductions of $1.4-$1.7B by 2027 and cash breakeven by 2028
  • Advancing vaccine and oncology pipelines; upcoming launches include next-gen COVID vaccine and flu + COVID combination
  • CEO prioritizes sales growth, late-stage pipeline focus, and cost efficiency; demand for COVID vaccination remains strong
Last Updated: 01/05/2025, 14:16
Read Full Transcript

Compare MRNA to Peers and Sector

Metrics to compare
MRNA
Peers
Sector
Relationship
P/E Ratio
−3.2x4.3x−0.5x
PEG Ratio
−0.07−0.020.00
Price/Book
1.1x1.5x2.6x
Price / LTM Sales
3.3x3.4x3.1x
Upside (Analyst Target)
13.5%139.5%48.3%
Fair Value Upside
Unlock3.6%7.6%Unlock

Analyst Ratings

5 Buy
17 Hold
4 Sell
Ratings:
26 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 47.64
(+74.17% Upside)

Earnings

Latest Release
May 01, 2025
EPS / Forecast
-2.52 / -3.18
Revenue / Forecast
108.00M / 115.30M
EPS Revisions
Last 90 days

MRNA Income Statement

People Also Watch

145.00
NVDA
+1.52%
85.62
UBER
-1.11%
199.86
ORCL
+13.31%
116.18
MU
+0.13%
812.03
LLY
+0.42%

FAQ

What Stock Exchange Does Moderna Trade On?

Moderna is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Moderna?

The stock symbol for Moderna is "MRNA."

What Is the Moderna Market Cap?

As of today, Moderna market cap is 10.58B.

What Is Moderna's Earnings Per Share (TTM)?

The Moderna EPS (TTM) is -8.72.

When Is the Next Moderna Earnings Date?

Moderna will release its next earnings report on 30 Jul 2025.

From a Technical Analysis Perspective, Is MRNA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Moderna Stock Split?

Moderna has split 0 times.

How Many Employees Does Moderna Have?

Moderna has 5800 employees.

What is the current trading status of Moderna (MRNA)?

As of 13 Jun 2025, Moderna (MRNA) is trading at a price of 27.35, with a previous close of 27.35. The stock has fluctuated within a day range of 26.81 to 27.93, while its 52-week range spans from 23.15 to 145.74.

What Is Moderna (MRNA) Price Target According to Analysts?

The average 12-month price target for Moderna is USD47.63636, with a high estimate of USD198 and a low estimate of USD20. 5 analysts recommend buying the stock, while 4 suggest selling, leading to an overall rating of Neutral. The stock has an +74.17% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.